General Announcement::Press Release

Issuer & Securities

Issuer/ Manager
BIOCON BIOLOGICS GLOBAL PLC
Securities
BIOCONBIO US$800M6.67%N291009A - US090978AA56 - RJUB
BIOCONBIO US$800M6.67%N291009R - USG11185AA61 - KSEB
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
30-Jan-2025 23:01:10
Status
New
Announcement Sub Title
Press Release
Announcement Reference
SG250130OTHRERLN
Submitted By (Co./ Ind. Name)
Biocon Biologics Limited / Akhilesh Nand
Designation
Company Secretary
Effective Date and Time of the event
31/01/2025 00:01:00
Description (Please provide a detailed description of the event in the box below)
Biocon Q3FY25 Revenue at Rs 3,856 Cr, Up 7%#, EBITDA at Rs 787 Cr, Up 16%#; Net Profit at Rs 25 Cr, Biosimilars^ Up 14%; Research Services Up 11%.

Attachments

PR_Biocon_BBL_Q3FY25_30012025_SGX.pdf
Total size =827K